In this study, we compared the in vivo efficacy of CCR4-IL2 IT versus the US Food and Drug Administration-approved drug, brentuximab, using an immunodeficient mouse CTCL model. This evidence concerns the gene IL2 and primary cutaneous T-cell non-Hodgkin lymphoma.